Once again, a major corporation picked a boutique over a Wall Street mega-bank to advise on its multi-billion dollar deal
REUTERS/Jeff Christensen
On one side of the deal, projected to be worth about $40 billion, is Teva Pharmaceuticals, which is aiming to buy its peer Mylan N.V. for $82 per share in a cash-and-stock deal. Teva, according to a statement, is being advised by Greenhill & Co., a boutique bank that went public in 2004.
It isn't yet clear who's advising on the other side of the deal, but Centerview Partners has been an advisor to Mylan N.V. in the past, and as recently as summer 2014.
If that's the case, it's yet another big win for an advisor that has been taking a growing portion of big banks' advisory fees, especially in 2015. And it's part of a pattern of smaller banks displacing boutiques, especially on some big deals.
Representatives for Teva Pharmaceuticals did not immediately comment when contacted by Business Insider; Centerview did not immediately comment.
- Indian markets could recover on Monday but earnings, global cues will decide the rest of the week, say experts
- Top temples to visit in India you must visit atleast once in a lifetime
- Top 10 adventure sports across India: Where to experience them in 2024
- Market recap: Valuation of 6 of top 10 firms declines by Rs 68,417 cr; Airtel biggest laggard
- West Bengal Elections: Rift among INDIA bloc partners triggers three-cornered intense contests
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market